Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19755566 | 0.84 | ALDH1A1 (0.48) | PTPN1ALDH1A1L3MBTL1MAPTTDP1 | |
| SCHEMBL18233757 | 0.82 | PTPN1 (0.48) | PTPN1P4HTML3MBTL1MAPTTDP1 | |
| SCHEMBL6876891 | 0.80 | ALDH1A1 (0.51) | PTPN1ALDH1A1L3MBTL1MAPTTDP1 | |
| SCHEMBL19625790 | 0.79 | ALDH1A1 (0.50) | PTPN1ALDH1A1P4HTML3MBTL1MAPT | |
| SCHEMBL4684596 | 0.79 | ALDH1A1 (0.50) | PTPN1ALDH1A1MAPTSMN1; SMN2MAOB | |
| SCHEMBL26260122 | 0.78 | PTPN1 (0.53) | PTPN1ALDH1A1P4HTML3MBTL1MAPT | |
| SCHEMBL4891121 | 0.77 | ALDH1A1 (0.55) | PTPN1ALDH1A1L3MBTL1MAPTTDP1 | |
| SCHEMBL3393935 | 0.77 | AGXT (0.40) | ALDH1A1CYP2C19SMN1; SMN2LMNAPOLB | |
| SCHEMBL83012 | 0.76 | ALDH1A1 (0.47) | PTPN1ALDH1A1L3MBTL1MAPTLMNA | |
| SCHEMBL10247270 | 0.75 | PTPN1 (0.49) | PTPN1ALDH1A1P4HTML3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000508-B2 | Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate | SHIONOGI & CO., LTD (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-9969750-B2 | Method of producing (3S,11aR)-6,8-dihalo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-diones | SHIONOGI AND CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20180044351-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180037592-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-02-08 | — | — | US | disclosed |
| US-20180037593-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-02-08 | — | — | US | disclosed |
| US-20180037591-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-02-08 | — | — | US | disclosed |
| US-9856271-B2 | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2018-01-02 | — | — | US | disclosed |
| US-20170369509-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9802959-B2 | Method of producing (4R,12aS)-7,9-dihalo-4-methyl-3,4,12,12a-tetrahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-6,8-diones | SHIONOGI & CO., LTD. (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-08-20 | — | — | US | disclosed |
| US-9051337-B2 | Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides | SHIONOGI & CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20150038702-A1 | Method of producing compounds having HIV integrase inhivitory activity | SHINOGI & CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
| US-20140200209-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE COMPANY (US) | 2014-07-17 | — | — | US | disclosed |
| US-8778943-B2 | Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-α]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides | SHIONOGI & CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140011995-A1 | Process for Preparing Compound Having HIV Integrase Inhibitory Activity | SHINOGI & CO., LTD (JP) | 2014-01-09 | — | — | US | disclosed |
| US-20130172559-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE COMPANY (US) | 2013-07-04 | — | — | US | disclosed |
| US-8410103-B2 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120208998-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | YOSHIDA HIROSHI (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | GLAXOSMITHKLINE LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038702-A1 | Method of producing compounds having HIV integrase inhivitory activity | XDH, IMPDH1, IMPA1 | PTPN1 2013/4885ALDH1A1 2362/4885P4HTM 1033/4885 |
| US-20180037592-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, DRD4, PYM1 | PTPN1 1750/4885ALDH1A1 2776/4885P4HTM 1363/4885 |
| US-20140200209-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | PTPN1 2364/4885ALDH1A1 3208/4885P4HTM 1139/4885 |
| US-20180044351-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | CYP3A4, DRD4, CCND2 | PTPN1 2970/4885ALDH1A1 2086/4885P4HTM 1080/4885 |
| US-10000508-B2 | Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate | DPYD, ODC1, PKD1 | PTPN1 4303/4885ALDH1A1 310/4885P4HTM 2269/4885 |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | PTPN1 2353/4885ALDH1A1 3222/4885P4HTM 1136/4885 |
| US-20120208998-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | CDKN1A, CDK2, CDK2AP1 | PTPN1 3803/4885ALDH1A1 2164/4885P4HTM 1484/4885 |
| US-20140011995-A1 | Process for Preparing Compound Having HIV Integrase Inhibitory Activity | DRD4, XDH, CCND2 | PTPN1 1503/4885ALDH1A1 3180/4885P4HTM 1309/4885 |
| US-20180155364-A1 | NOVEL PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CYP3A5, SAMHD1, CYP3A43 | PTPN1 4214/4885ALDH1A1 1838/4885P4HTM 3110/4885 |
| US-20180037593-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, DRD4, PYM1 | PTPN1 1750/4885ALDH1A1 2776/4885P4HTM 1363/4885 |
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | PTPN1 2028/4885ALDH1A1 2929/4885P4HTM 739/4885 |
| US-20180037591-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, DRD4, PYM1 | PTPN1 1750/4885ALDH1A1 2776/4885P4HTM 1363/4885 |
| US-20130172559-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | PTPN1 2353/4885ALDH1A1 3222/4885P4HTM 1136/4885 |
| US-20170369509-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | PTPN1 2364/4885ALDH1A1 3208/4885P4HTM 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.